文献速递传染病防控与疫情报告免疫规划

基于改良安卡拉痘苗病毒载体的A24型口蹄疫疫苗在牛中的评价

Evaluation of modified Vaccinia Ankara-based vaccines against foot-and-mouth disease serotype A24 in cattle.
PubMed 文献 · Vaccine · 2019-11-09

为应对新出现的口蹄疫病毒野毒株,研究以改良安卡拉痘苗病毒安卡拉-巴伐利亚北欧(MVA-BN®)为载体平台,构建表达A24 Cruzeiro P1衣壳多蛋白和不同3C蛋白酶变体的重组疫苗。四种构建体经体外筛选,两种符合临床研究标准;两者在牛中安全,多次接种后诱导低至中等血清中和滴度,同源攻毒后单剂或prime-boost方案均提供100%临床保护和病毒血症保护,并可区分感染与免疫动物。

要点

  • MVA-BN载体可携带并表达多个口蹄疫病毒株抗原,且有人用广泛安全性记录。
  • 两种构建体MVA-mBN360B和MVA-mBN386B符合体外标准进入临床研究。
  • 牛体试验中两种疫苗安全,同源攻毒后单剂或prime-boost均获100%临床和病毒血症保护。

核心结论

  • MVA-BN作为口蹄疫疫苗载体成功应用,为针对更具流行病学相关性口蹄疫病毒株的进一步疫苗开发提供了平台。

研究设计与样本

  • 研究构建并体外评价四种MVA-BN-FMD构建体,筛选出两种符合临床研究标准的构建体,随后在牛中评价安全性和免疫原性及攻毒保护。

主要发现

  • 两种疫苗在牛中安全,多次接种后诱导针对口蹄疫病毒的低至中等血清中和滴度。
  • 同源攻毒后,单剂或prime-boost免疫方案均提供100%临床口蹄疫保护和100%病毒血症保护。
  • MVA-BN口蹄疫疫苗平台能够区分感染动物与接种动物(DIVA)。

关键数值与推荐

  • 四种MVA-BN-FMD构建体体外评价载体稳定性、FMDV P1多蛋白表达、加工及疫苗放大生产潜力,其中MVA-mBN360B(携带C142T突变3C蛋白酶和HIV移码以减少表达)和MVA-mBN386B(携带L127P突变3C蛋白酶)符合体外选择标准。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

To prepare foot-and-mouth disease (FMD) recombinant vaccines in response to newly emerging FMD virus (FMDV) field strains, we evaluated Modified Vaccinia virus Ankara-Bavarian Nordic (MVA-BN®) as an FMD vaccine vector platform. The MVA-BN vector has the capacity to carry and express numerous foreign genes and thereby has the potential to encode antigens from multiple FMDV strains. Moreover, this vector has an extensive safety record in humans. All MVA-BN-FMD constructs expressed the FMDV A24 Cruzeiro P1 capsid polyprotein as antigen and the FMDV 3C protease required for processing of the polyprotein. Because the FMDV wild-type 3C protease is detrimental to mammalian cells, one of four FMDV 3C protease variants were utilized: wild-type, or one of three previously reported mutants intended to dampen protease activity (C142T, C142L) or to increase specificity and thereby reduce adverse effects (L127P). These 3C coding sequences were expressed under the control of different promoters selected to reduce 3C protease expression. Four MVA-BN-FMD constructs were evaluated in vitro for acceptable vector stability, FMDV P1 polyprotein expression, processing, and the potential for vaccine scale-up production. Two MVA-BN FMD constructs met the in vitro selection criteria to qualify for clinical studies: MVA-mBN360B (carrying a C142T mutant 3C protease and an HIV frameshift for reduced expression) and MVA-mBN386B (carrying a L127P mutant 3C protease). Both vaccines were safe in cattle and elicited low to moderate serum neutralization titers to FMDV following multiple dose administrations. Following FMDV homologous challenge, both vaccines conferred 100% protection against clinical FMD and viremia using single dose or prime-boost immunization regimens. The MVA-BN FMD vaccine platform was capable of differentiating infected from vaccinated animals (DIVA). The demonstration of the successful application of MVA-BN as an FMD vaccine vector provides a platform for further FMD vaccine development against more epidemiologically relevant FMDV strains.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Steigerwald R, Brake DA, Barrera J, et al. Evaluation of modified Vaccinia Ankara-based vaccines against foot-and-mouth disease serotype A24 in cattle. Vaccine. 2019. PMID: 31718901. doi:10.1016/j.vaccine.2019.10.103

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。